BUILT TO TRANSLATE A BREAKTHROUGH DISCOVERY.
Goldenrod brings together academic discovery, company-building experience, federal support, and disease-focused collaborators to advance a differentiated PDE4 program toward the clinic.
THE PATH FROM UNMC TO GOLDENROD.
01
UNMC DISCOVERY
Dr. Corey Hopkins and colleagues developed the medicinal chemistry that produced GR1 and its related intellectual property.
02
FANNIN IN-LICENSE
Fannin Innovation Studio identified the translational opportunity and licensed the program from the University of Nebraska Medical Center.
03
PROGRAM BUILD
Fannin assembled the early development plan, company infrastructure, grants, collaborators, and supporting pharmacology.
04
GOLDENROD SPIN-OUT
Goldenrod Therapeutics became the dedicated company advancing GR1 and the broader PDE4 portfolio toward clinical development.
A TEAM BUILT FOR TRANSLATION
-
Dev Chatterjee, MD, MS, PhD
Chief Executive Officer
-
Atul Varadhachary, MD, PhD
President
-
Mark Worscheh, MBA
Chief Financial Officer
-
Ross H. Clary, BS
Vice President, Investment Relations
-
Secondra Holmes, PhD
Senior Associate, Business Development
-
Leniher Castan, PhD
Senior Scientist
OUR COLLABORATORS
-
Corey Hopkins, PhD
Professor
University of Nebraska Medical Center
-
Sara Jane Ward, PhD
Associate Professor
Temple University
-
Elisabetta Soragni, PhD
Chief Scientific Officer
Friedreich’s Ataxia Research Alliance
-
Hélène Puccio, PhD
Senior Researcher
INSERM
-
Nigel H. Greig, PhD
Senior Investigator
National Institute of Aging
-
Sarah C. Hopp, Ph.D
Associate Professor
The University of Texas at San Antonio